

Why this solution/product is innovative, the broad implications for future research, and/or how it will improve the human condition?

The Promise of Prescription Digital Therapeutics

PDTs leverage digital's centrality to our daily lives, advancing the future of modern medicine and elevating the standard of care.

Build relationships with patients



Iteratively improve therapies



Generate concurrent evidence



Personalize treatment journey



Improve patient outcomes and efficacy



Increase access to cost effective treatment



Click Therapeutics

Our industry-leading platform enables us to apply our learnings across all our products


Digital Mechanisms of Action [25+]
The mechanisms that enable shifts in neuroactivity, driving efficacy

Discovery MOAs (DiNaMo¹)

Proprietary interventions that aim to target or correct specific neural pathways that are faulty through structured audiovisual, haptic, and cognitive stimuli
i.e., Emotional Faces Memory Task, Attention Bias Modification Task

Translational MOAs

Digitized version of widely accepted evidence-based treatment mechanisms, optimized for smartphone use
i.e., Cognitive Behavioral Therapy, Mindfulness Training, Acceptance & Commitment Therapy



These are the building blocks of innovative new PDTs, enabling us to create targeted treatments that integrate efficacy, engagement, and personalization for sustained, multi-modal action.

Our products are built on this common tech infrastructure, increasing development speed.



Click Therapeutics

Our digital therapeutics match the clinical and regulatory rigor of pharmacologic therapies while offering improved clinical effectiveness and shorter development timelines



	Molecular Therapies	Prescription Digital Therapeutics
Similarities	Prescription required	Rx Requirements
	Clinically validated through robust clinical trials	Clinical Validation
	FDA approved	Regulatory Paradigm
DTx offer advantages	Orally, subcutaneously, IV infusion or topically	Delivered via mobile device, potentially with other therapeutics
	Difficult to monitor outside of regularly-scheduled visits	Adherence
	Regular risk of side effects	Safety Profile
	Difficult to track and requires substantial investment	Data Collection
	10-12 years	Time to Market
	Threat of generic or biosimilar competition	Life Cycle Management
		Compliance monitored and tracked in real-time
		Generally low risk of side effects / adverse events
		Real World Data (RWD) collection generates powerful insights
		2-4 years (far lower cost + higher PTRS)
		Continuous product improvement (hard to genericize)


Health & Wellness Apps lack these key features



Click Therapeutics

Click Decentralized Clinical Trials Geography

STATE	TOTAL	STATE	TOTAL
TX	93	IA	17
NY	87	OK	17
CA	71	KS	16
FL	64	MS	14
PA	62	NV	13
OH	51	UT	13
NC	49	WV	12
IL	40	CT	11
NJ	36	AR	11
MI	34	MT	10
TN	33	LA	9
AZ	33	NM	8
GA	31	NE	7
VA	30	ME	7
IN	29	RI	6
MO	28	WY	5
MD	28	DE	5
WA	27	ND	5
SC	27	VT	4
WI	22	HI	4
MA	22	SD	3
CO	22	NH	3
AL	22	ID	3
KY	20	AK	1
MN	19		
OR	18		
Grand Total			1202



Note: Does not include CT-101-002, data not available